Giulia Sierri, Michela Patrucco, Davide Ferrario, Antonio Renda, Susanna Comi, Matilde Ciprandi, Veronica Fontanini, Francesco Saverio Sica, Silvia Sesana, Marta Costa Verdugo, Marcelo Kravicz, Luca Salassa, Marta Busnelli, Francesca Re
{"title":"Targeting specific brain districts for advanced nanotherapies: A review from the perspective of precision nanomedicine","authors":"Giulia Sierri, Michela Patrucco, Davide Ferrario, Antonio Renda, Susanna Comi, Matilde Ciprandi, Veronica Fontanini, Francesco Saverio Sica, Silvia Sesana, Marta Costa Verdugo, Marcelo Kravicz, Luca Salassa, Marta Busnelli, Francesca Re","doi":"10.1002/wnan.1991","DOIUrl":null,"url":null,"abstract":"Numerous studies are focused on nanoparticle penetration into the brain functionalizing them with ligands useful to cross the blood–brain barrier. However, cell targeting is also crucial, given that cerebral pathologies frequently affect specific brain cells or areas. Functionalize nanoparticles with the most appropriate targeting elements, tailor their physical parameters, and consider the brain's complex anatomy are essential aspects for precise therapy and diagnosis. In this review, we addressed the state of the art on targeted nanoparticles for drug delivery in diseased brain regions, outlining progress, limitations, and ongoing challenges. We also provide a summary and overview of general design principles that can be applied to nanotherapies, considering the areas and cell types affected by the most common brain disorders. We then emphasize lingering uncertainties that hinder the translational possibilities of nanotherapies for clinical use. Finally, we offer suggestions for continuing preclinical investigations to enhance the overall effectiveness of precision nanomedicine in addressing neurological conditions.","PeriodicalId":501345,"journal":{"name":"WIREs Nanomedicine and Nanobiotechnology","volume":"46 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"WIREs Nanomedicine and Nanobiotechnology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/wnan.1991","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Numerous studies are focused on nanoparticle penetration into the brain functionalizing them with ligands useful to cross the blood–brain barrier. However, cell targeting is also crucial, given that cerebral pathologies frequently affect specific brain cells or areas. Functionalize nanoparticles with the most appropriate targeting elements, tailor their physical parameters, and consider the brain's complex anatomy are essential aspects for precise therapy and diagnosis. In this review, we addressed the state of the art on targeted nanoparticles for drug delivery in diseased brain regions, outlining progress, limitations, and ongoing challenges. We also provide a summary and overview of general design principles that can be applied to nanotherapies, considering the areas and cell types affected by the most common brain disorders. We then emphasize lingering uncertainties that hinder the translational possibilities of nanotherapies for clinical use. Finally, we offer suggestions for continuing preclinical investigations to enhance the overall effectiveness of precision nanomedicine in addressing neurological conditions.